GERD treatment typically starts with lifestyle changes and over-the-counter acid-reducing medication, then escalates to prescription drugs or surgery if symptoms persist. Most people can manage their reflux effectively without procedures, but the right approach depends on how severe your symptoms are and whether they’ve caused damage to your esophagus.
Lifestyle Changes That Make a Real Difference
Weight loss is one of the most effective non-drug interventions for GERD. A hospital-based study found that losing 5 to 10% of body weight in women, and more than 10% in men, led to significant reductions in overall symptom scores. Longer-term data showed that a BMI decrease of about 3.5 points reduced the risk of frequent reflux symptoms by nearly 40%. If you’re carrying extra weight, this is one of the few changes that addresses a root cause of reflux rather than just masking symptoms.
Certain foods weaken the muscular valve between your esophagus and stomach, making reflux more likely. Fatty meals trigger the release of a gut hormone that interferes with this valve’s ability to stay closed. Caffeine, chocolate, and alcohol also reduce the valve’s resting pressure, meaning acid can escape upward more easily. Citrus and tomato-based foods don’t necessarily weaken the valve but can irritate an already inflamed esophagus. You don’t need to eliminate every possible trigger at once. Start by cutting the most common offenders for a few weeks and see what your body tells you.
How you sleep matters too. Elevating the head of your bed by 6 to 12 inches, using a wedge pillow angled at 30 to 45 degrees, helps gravity keep stomach acid where it belongs. Stacking regular pillows doesn’t work as well because it bends you at the waist rather than elevating your entire upper body. Sleeping on your left side also helps, since the anatomy of your stomach in that position makes it harder for acid to reach the esophagus. Eating your last meal at least two to three hours before lying down gives your stomach time to empty.
Over-the-Counter Medications
Antacids neutralize acid that’s already in your stomach. They work fast, often within minutes, but the relief is temporary. They’re fine for occasional heartburn but not practical as a daily strategy for GERD.
H2 blockers like famotidine reduce the amount of acid your stomach produces. A single dose starts working within about an hour, reaches peak effectiveness in one to three hours, and lasts 10 to 12 hours. These are a good option for people with mild to moderate symptoms, especially nighttime reflux when taken before bed. They’re available without a prescription and are generally well tolerated.
Proton pump inhibitors (PPIs) like omeprazole and lansoprazole are stronger acid suppressors and the most effective medication class for GERD. Over-the-counter versions are widely available. Unlike H2 blockers, PPIs take a few days to reach full effect because they work by gradually shutting down the acid-producing pumps in your stomach lining. They’re meant to be taken daily, typically 30 minutes before your first meal.
Prescription-Strength Acid Suppression
When over-the-counter PPIs at standard doses don’t control your symptoms, your doctor may prescribe a higher dose or a different PPI. The 2022 guidelines from the American College of Gastroenterology recommend an initial PPI course of 8 weeks. After that, the next step depends on what’s happening inside your esophagus.
If an upper endoscopy shows moderate to severe erosive damage (classified as grade C or D), long-term daily PPI therapy is recommended indefinitely. For people without visible erosion or whose esophagus has healed, the guidelines suggest trying to step down: switching to a lower dose, using the medication only on days when symptoms flare, or stopping altogether. Many people find they can manage with intermittent use once the initial inflammation has resolved.
A newer class of acid suppressors called potassium-competitive acid blockers (vonoprazan is the most studied) works through a different mechanism and kicks in faster than traditional PPIs. In a large clinical trial, vonoprazan healed erosive esophagitis in 75% of patients at just 2 weeks compared to 68% with a standard PPI. By 8 weeks, both reached roughly 92% healing rates. The biggest advantage showed up in patients with more severe erosion, where vonoprazan had a notable early lead. These medications are newer and not yet as widely prescribed, but they’re an option when standard PPIs fall short.
Long-Term PPI Safety
You may have heard concerns about PPIs causing bone fractures, vitamin B12 deficiency, or kidney problems. Higher-quality studies have been reassuring on this front. The best available evidence has not demonstrated an increased risk of osteoporosis-related fractures or meaningful vitamin and mineral deficiencies with long-term PPI use. For patients without specific risk factors, routine bone density monitoring or B12 supplementation isn’t considered necessary while on PPIs.
That said, the general principle still applies: use the lowest effective dose for the shortest appropriate duration. If your symptoms are well controlled and you don’t have erosive damage or Barrett’s esophagus, it’s reasonable to try stepping down. Patients with complicated GERD, including a history of severe erosion, esophageal ulcers, or narrowing of the esophagus, should generally stay on their PPI rather than experimenting with discontinuation.
Surgical and Procedural Options
Surgery is typically reserved for people who can’t tolerate medications, don’t want lifelong drug therapy, or have persistent symptoms despite maximum medical treatment. The two most established surgical options are fundoplication and magnetic sphincter augmentation.
Fundoplication (the Nissen procedure) wraps the top of your stomach around the lower esophagus to reinforce the weak valve. It’s been performed for decades and has strong long-term data. About 81.5% of patients are able to stop PPIs after the procedure. The tradeoff is that it can make it difficult to belch or vomit afterward. Only about 66% of fundoplication patients retain a normal ability to belch, and roughly half lose the ability to vomit.
Magnetic sphincter augmentation (the LINX device) places a ring of tiny magnetic beads around the lower esophagus. The magnets are strong enough to keep the valve closed against reflux but weak enough to open when you swallow. PPI elimination rates are virtually identical to fundoplication at about 81%. The key advantage is that it preserves normal function much better: 95% of patients retain the ability to belch and 94% can still vomit. This matters more than it might sound, since the inability to release gas causes significant bloating and discomfort for some fundoplication patients.
A less invasive option called transoral incisionless fundoplication (TIF) is performed through the mouth with an endoscope, leaving no external incisions. It’s best suited for a specific patient profile: BMI under 35, hiatal hernia smaller than 2 centimeters, and confirmed GERD without severe erosive damage. In a multicenter study, 94% of patients achieved clinical success after TIF. Patient satisfaction jumped from 8% before the procedure to 79% afterward, and 80% of patients who were on daily PPIs before the procedure were able to stop or use them only occasionally.
Why Treatment Matters Beyond Symptom Relief
Chronic, uncontrolled acid reflux can cause changes to the lining of the esophagus, a condition called Barrett’s esophagus. Barrett’s is a precursor to esophageal cancer, though the absolute risk of progression is low. PPI therapy appears to offer some protection: in North American studies, PPI use was associated with a 53% lower risk of developing esophageal cancer in Barrett’s patients. A large randomized trial of over 2,500 Barrett’s patients found that higher-dose PPI therapy reduced a combined outcome of death, cancer, or precancerous changes compared to lower doses, with a number needed to treat of 37 over eight years.
Notably, antireflux surgery has not been shown to prevent esophageal cancer any better than medication alone. The cancer rates were 3.8 per 1,000 patient-years with surgery versus 5.3 with medical therapy, a difference that was not statistically significant. This means the decision to pursue surgery should be driven by symptom control and quality of life rather than cancer prevention.